文献速递癫痫

癫痫女性中叶酸与早产、子痫前期及胎儿生长受限风险:一项前瞻性队列研究

Folic Acid and Risk of Preterm Birth, Preeclampsia, and Fetal Growth Restriction Among Women With Epilepsy: A Prospective Cohort Study.
PubMed 文献 · Neurology · 2022-05-16

该研究基于挪威母亲与儿童队列研究(MoBa)1999-2008年的100,105例单胎妊娠,其中316例孕期使用抗癫痫发作药物(ASM)的癫痫女性、358例未治疗癫痫女性。结果显示,在使用ASM的癫痫女性中,围受孕期未补充叶酸者(n=64)早产风险高于补充者(n=245,参照组)(aOR 3.3,95%CI 1.2-9.2);叶酸与子痫前期或小于胎龄儿风险无关。

要点

  • 使用ASM的癫痫女性中,围受孕期补充叶酸与早产风险降低相关(aOR 3.3,95%CI 1.2-9.2,未补充 vs 补充)。
  • 使用ASM的癫痫女性中,叶酸与子痫前期或小于胎龄儿风险无关。
  • 未使用ASM的癫痫女性及无癫痫女性中,叶酸与早产风险无关。

核心结论

  • 在使用ASM的癫痫女性中,围受孕期补充叶酸与早产风险降低相关。
  • 该发现支持推荐:使用ASM的育龄期癫痫女性应规律补充叶酸。
  • 该研究提供III级证据表明围受孕期补充叶酸可降低使用ASM的癫痫女性早产风险。

研究设计与样本

  • 前瞻性挪威母亲与儿童队列研究(MoBa)1999-2008年纳入的单胎妊娠。
  • 共纳入100,105例妊娠:99,431例无母体癫痫,316例母体癫痫且孕期使用ASM,358例未治疗母体癫痫。
  • 暴露为围受孕期叶酸补充,定义为孕前4周至孕12周内摄入,由母亲在孕17-19周回顾性回忆收集。

主要发现

  • 使用ASM的癫痫女性中,未补充围受孕期叶酸者(n=64)早产风险高于补充者(n=245,参照组)(aOR 3.3,95%CI 1.2-9.2)。
  • 参照组(补充叶酸的使用ASM癫痫女性)早产风险与围受孕期补充叶酸的无癫痫女性相似(aOR 0.9,95%CI 0.5-1.6)。
  • 使用ASM的癫痫女性中,孕早期后开始补充叶酸者早产风险高于叶酸补充时机相似的无癫痫女性(aOR 2.6,95%CI 1.1-6.5),未补充叶酸者风险更高(aOR 9.4,95%CI 2.6-34.8)。
  • 未使用ASM的癫痫女性及无癫痫女性中,叶酸与早产风险无关。
  • 癫痫女性中叶酸与子痫前期或小于胎龄儿风险无关。

关键数值与推荐

  • 早产定义为出生时胎龄<37周。
  • 主要结局为早产、小于胎龄儿(SGA)和子痫前期。

临床怎么用

  • 作者结论认为,使用ASM的育龄期癫痫女性应规律补充叶酸。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Women with epilepsy treated with antiseizure medication (ASM) have increased risk of pregnancy complications including preterm birth, fetal growth restriction, and preeclampsia. We aimed to investigate whether folic acid supplementation is associated with these pregnancy complications in women with epilepsy using ASM. METHODS: Singleton pregnancies in the prospective Norwegian Mother and Child Cohort Study (MoBa) (1999-2008) were included. Information on maternal epilepsy, ASM, folic acid supplementation, and pregnancy outcomes was obtained from the MoBa questionnaires and the Norwegian Medical Birth Registry. The main exposure, periconceptional folic acid supplementation, was defined as intake between 4 weeks before pregnancy and 12 weeks into pregnancy, retrospectively collected by recall of the mothers in weeks 17-19. The primary outcomes were preterm birth (gestational age <37 weeks at birth), small for gestational age (SGA), and preeclampsia. RESULTS: The study included 100,105 pregnancies: 99,431 without maternal epilepsy, 316 with maternal epilepsy and ASM exposure in pregnancy, and 358 with untreated maternal epilepsy. Among ASM-treated women with epilepsy, the risk of preterm birth was higher in those who did not use periconceptional folic acid (n = 64) compared with those who did (n = 245, the reference) (adjusted odds ratio [aOR] 3.3, 95% CI 1.2-9.2), while the risk of preterm birth among the reference was similar to the risk among women without epilepsy using folic acid periconceptionally (aOR 0.9, 95% CI 0.5-1.6). ASM-treated women with epilepsy starting folic acid after the first trimester had a higher risk compared with women without epilepsy with similar timing of folic acid (aOR 2.6, 95% CI 1.1-6.5), and even higher if not using folic acid (aOR 9.4, 95% CI 2.6-34.8). Folic acid was not associated with risk of preterm birth among women with epilepsy without ASM or among women without epilepsy. Folic acid was not associated with risk of preeclampsia or SGA among women with epilepsy. DISCUSSION: In women with epilepsy using ASM, periconceptional folic acid was associated with a lower risk of preterm birth. This finding supports the recommendation that ASM-treated women with epilepsy of childbearing potential should use folic acid supplementation on a regular basis. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for women with epilepsy using ASM, periconceptional folic acid supplementation decreases the risk of preterm birth.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Alvestad S, Husebye ESN, Christensen J, et al. Folic Acid and Risk of Preterm Birth, Preeclampsia, and Fetal Growth Restriction Among Women With Epilepsy: A Prospective Cohort Study. Neurology. 2022. PMID: 35577577. doi:10.1212/WNL.0000000000200669

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。